Trial Profile
A multi-center, double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of 14-day inhaled TPI ASM8 in subjects with asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs ASM 8 (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 14 Dec 2008 Trial end date changed from 1 Jul 2008 to 1 Oct 2008 as reported by Clinicaltrials.gov.
- 14 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.